Bristol-Myers Squibb Rights
CELG.RT
28 hedge funds and large institutions have $248K invested in Bristol-Myers Squibb Rights in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 27 → 28 (+1)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
15% less capital invested
Capital invested by funds: $291K → $248K (-$42.7K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5L
55I LLC
Boston,
Massachusetts
|
+$38.9K |
| 2 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$9.06K |
| 3 |
GGI
Godsey & Gibb Inc
Richmond,
Virginia
|
+$8.61K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.32K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCA
Transcend Capital Advisors
Madison,
New Jersey
|
-$56K |
| 2 |
QCG
Quadrant Capital Group
Cincinnati,
Ohio
|
-$11K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
-$9.56K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6K |
| 5 |
HR
Howe & Rusling
Rochester,
New York
|
-$1K |
CELG.RT Hedge Fund Activity: Q2 2020 in Review
28 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q2 2020, worth a combined $248K — down 15% from $291K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CELG.RT positions and 6 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was 55I LLC, opening a new position worth an estimated $38.9K. The largest seller was Transcend Capital Advisors, exiting entirely with an estimated $56K sold.
- 28 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q2 2020, up from 27 in Q1 2020.
- Funds reported $248K of Bristol-Myers Squibb Rights stock for Q2 2020, down 15% quarter-over-quarter.
- 7 funds opened new Bristol-Myers Squibb Rights positions in Q2 2020 and 6 closed out, a net change of +1 holder.
- The largest Bristol-Myers Squibb Rights buyer in Q2 2020 was 55I LLC, an estimated $38.9K added.
- The largest Bristol-Myers Squibb Rights seller in Q2 2020 was Transcend Capital Advisors, an estimated $56K sold.
Based on aggregated 13F filings for Q2 2020.